©The Author(s) 2026.
World J Gastroenterol. Jan 28, 2026; 32(4): 115040
Published online Jan 28, 2026. doi: 10.3748/wjg.v32.i4.115040
Published online Jan 28, 2026. doi: 10.3748/wjg.v32.i4.115040
Table 2 Clinical characteristics and antibiotic consumption differences between 2015-2019 and 2020-2024 (inflammatory bowel disease population), n (%)
| Variables | 2015-2019 (n = 102) | 2020-2024 (n = 270) | P value |
| Age, year, median (IQR) | 49.50 (37.00, 61.00) | 50.00 (31.50, 62.00) | 0.887 |
| Length of stay, day(s), median (IQR) | 10.00 (6.00, 14.00) | 11.00 (7.00, 15.00) | 0.379 |
| Hospitalization costs, 1000 CNY, median (IQR) | 7.63 (5.27, 15.11) | 9.72 (5.94, 16.36) | 0.812 |
| Rate, % | 33.89 | 15.93 | < 0.001 |
| DDDs per 100 bed-days, median (IQR) | 49.54 (24.29, 78.57) | 68.73 (43.75, 85.96) | < 0.001 |
| Classifications | |||
| β-lactam antimicrobials/penicillins | 44 (43.2) | 140 (51.8) | 0.134 |
| Cephalosporins | 34 (33.3) | 68 (25.2) | 0.116 |
| Fluoroquinolones | 11 (10.8) | 39 (14.4) | 0.356 |
| Imidazole derivatives | 13 (12.7) | 10 (3.8) | 0.001 |
| Carbapenems | 0 (0) | 5 (1.9) | |
| Glycopeptide antibacterials | 0 (0) | 6 (2.2) | |
| Other antibacterials | 0 (0) | 2 (0.7) |
- Citation: Zeng W, Zhang WK, Xu D, He K, Huang YP, Liu YX, Yang HF. Antibiotic consumption of inpatients with inflammatory bowel disease during 2015-2024 and future prediction: Evidence from a general hospital. World J Gastroenterol 2026; 32(4): 115040
- URL: https://www.wjgnet.com/1007-9327/full/v32/i4/115040.htm
- DOI: https://dx.doi.org/10.3748/wjg.v32.i4.115040